Loading
A phase 2 trial of Durvalumab, Oleclumab, Monalizumab in non-small-cell lung cancer and small-cell lung cancer, run by AstraZeneca, now recruiting.
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer is a phase 2 interventional study registered as NCT05061550 by AstraZeneca, with 630 participants planned, started 2022-04-14 and due to reach its primary completion in 2030-05-28. Interventions recorded: Durvalumab, Oleclumab, Monalizumab, Dato-DXd, AZD0171. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Monalizumab, Oleclumab, AstraZeneca, Non-small-cell lung cancer.
Shares Oleclumab, Durvalumab, AstraZeneca, Small-cell lung cancer.
Shares Monalizumab, Oleclumab, Durvalumab, AstraZeneca.
Shares Datopotamab deruxtecan, Resectable stage I to III non-small-cell lung cancer, AstraZeneca, Cisplatin.
Shares Resectable stage I to III non-small-cell lung cancer, AstraZeneca, Cisplatin, Carboplatin.
Shares Resectable stage I to III non-small-cell lung cancer, Durvalumab, AstraZeneca, Small-cell lung cancer.
Shares Datopotamab deruxtecan, Durvalumab, AstraZeneca, Cisplatin.
Shares Datopotamab deruxtecan, AstraZeneca, Cisplatin, Carboplatin.